Literature DB >> 7569346

Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders.

D A Adelberg1, L V Del Priore, H J Kaplan.   

Abstract

OBJECTIVE: A retrospective analysis of patients who underwent surgical removal of subfoveal neovascular membranes caused by factors other than age-related macular degeneration (AMD) and presumed ocular histoplasmosis syndrome (POHS) was performed.
METHODS: 17 eyes (16 patients) were identified in which subfoveal neovascularization was caused by myopic degeneration (5 eyes), angioid streaks (5 eyes of 4 patients), idiopathic neovascularization (4 eyes), punctate inner choroidopathy (1 eye), multifocal choroiditis (1 eye), or candida chorioretinitis (1 eye).
RESULTS: Visual acuity remained stable after surgery in 10 of 17 eyes (59%), improved by 2 or more Snellen lines in 6 eyes (35%) and decreased in 1 eye (6%). Preoperative visual acuity was 20/80 or better in only 1 of 17 eyes (6%), but 5 of 17 eyes (29%) achieved postoperative visual acuity of 20/80 or better. Intraoperative and postoperative complications included peripheral retinal tears (1 eye), peripheral rhegmatogenous retinal detachment (1 eye), and mild cataract formation (1 eye). Subretinal neovascularization recurred after surgical removal in 4 eyes, 2 of which underwent repeat surgery.
CONCLUSION: Visual acuity remained stable or improved in 94% of eyes after surgical removal of subfoveal neovascularization, but postoperative visual acuity better than 20/80 was achieved in a minority of eyes.

Entities:  

Mesh:

Year:  1995        PMID: 7569346     DOI: 10.1097/00006982-199515030-00003

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors:  J M Ruiz-Moreno; C de la Vega
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

3.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

Review 4.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  Scanning and transmission electron microscopic findings during RPE wound healing in vivo.

Authors:  A Oganesian; E Bueno; Q Yan; C Spee; J Black; N A Rao; P F Lopez
Journal:  Int Ophthalmol       Date:  1997       Impact factor: 2.031

6.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

Review 7.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

8.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

Authors:  D S C Lam; W-M Chan; D T L Liu; D S P Fan; W W Lai; K K L Chong
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

9.  Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

10.  Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.

Authors:  J M Ruiz-Moreno; J A Montero
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.